
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc has demonstrated a robust growth trajectory, with Q3 revenue increasing by 31% year-over-year to $18,942, primarily driven by an 89% rise in Nociscan report volumes, indicating strong market demand for its innovative healthcare technology. The company is also expanding its presence through significant commercial agreements with well-established medical institutions, enhancing its market penetration and potential for revenue growth. Furthermore, the positive impact of favorable coverage decisions from private health insurers in the UK suggests that Nociscan adoption is accelerating, contributing to a strong outlook for future performance.
Bears say
Aclarion Inc faces significant challenges stemming from slower than expected traction with both surgeons and payers, which undermines the company's ability to grow its revenue from the Nociscan platform. Additionally, ongoing adjustments to FY25 earnings per share estimates indicate a troubling increase in operating expenses, with projections being downgraded to as low as $(15.13). The company's financial outlook is further complicated by balance sheet and liquidity risks, as well as uncertainties surrounding regulatory approvals, commercialization efforts, and reimbursement adequacy.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares